Eiger BioPharmaceuticals, Inc.
EIGR
Rangering i aksjer
#36458
Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company... Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and bringing to market targeted therapies for rare and ultra-rare diseases across the United States and internationally. Its primary investigational drug, Lonafarnib, an orally administered small molecule, is currently undergoing Phase III clinical trials for the treatment of hepatitis delta virus (HDV) infection. Other promising candidates in its portfolio include Lambda, which has completed Phase II clinical trials and is designed to target type III interferon receptors; Lonafarnib, also being evaluated for progeria and progeroid laminopathies; and Avexitide, an agent for congenital hyperinsulinism that has also successfully concluded Phase II studies for post-bariatric hypoglycemia. Established in 2008, Eiger BioPharmaceuticals, Inc. maintains its headquarters in Palo Alto, California.
Aksjekurs
$1.73
Sist synkronisert: 2025-06-17
Markedsverdi
$2.55M
Endring (1 dag)
-0.29%
Endring (1 år)
-79.71%
Land
US
Handel Eiger BioPharmaceuticals, Inc. (EIGR)
Kategori
Healthcare
P/S-forhold for Eiger BioPharmaceuticals, Inc. (EIGR)
P/S-forhold per October 2026 TTM: 0.80
Ifølge Eiger BioPharmaceuticals, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/S-forhold (TTM) 0.80. Ved slutten av 2022 hadde selskapet et P/S-forhold på 3.64.
P/S-historikk for Eiger BioPharmaceuticals, Inc. fra 2016 til 2026
P/S-forhold ved hvert års slutt
| År | P/S-forhold | Endre |
|---|---|---|
| 2026 (TTM) | 0.80 | 20.91% |
| 2023 | 0.66 | -81.89% |
| 2022 | 3.64 | -74.89% |
| 2021 | 14.51 | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
| 2017 | 0.00 | 0.00% |
| 2016 | 0.00 | 0.00% |
P/S-forhold for lignende selskaper eller konkurrenter
| Selskap | P/S-forhold | Forskjell i P/S-forhold | Land |
|---|---|---|---|
| 10.02 | 1,155.90% |
US
|
|
| 40.55 | 4,981.55% |
US
|
|
| 3.96 | 396.38% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | 1,171.47% |
NL
|
